CD99

CD99

a type I transmembrane protein present on thymocytes, lymphocytes, and myeloid cells involved in rosette formations with sheep erythrocytes.
Mentioned in ?
References in periodicals archive ?
Conventional markers of SFT including diffuse strong positive of CD34,[11] moderately positive of BcL-2 and CD99, and absence of S100, actin, and DOG1.[4],[8] Furthermore, newer immunohistochemistry STAT6 test to detect NAB2-STAT6 fusion gene had been used to differentiate SFT from other mimics and reached significant high sensitivity and specificity.[12],[13] In our case, both histologic characteristics and immunohistochemistry tests showed classic SFT appearance.
The immunohistochemical results were as follows: Vimentin (+), CD34 (+), Ki-67 (+), CD99 (+), and Bcl-2 (+) (Figs.
La histopatologia de la muestra, obtenida por biopsia percutanea con aguja cortante de la lesion, reporto un tumor fusocelular de aspecto benigno que pudiera tratarse de un tumor fibroso de la pleura; posteriormente, la inmunohistoquimica confirmo el diagnostico por inmunoreactividad de las celulas tumorales para BCL2, CD34, CD99 y STAT6 compatible con un tumor fibroso solitario.
Primary vulvar and vaginal extraosseous ewing's sarcoma/peripheral neuroectodermal tumor: Diagnostic confirmation with CD99 immunostaining and reverse transcriptase-polymerase chain reaction.
Further on immunohistochemistry, tumour showed CK, Chromogranin A, NSE in epithelial component; CD99 focally positive in epithelial component; Vimentin diffusely positive in stromal and focally positive in epithelial component; Ki67 focally high in epithelial component; Myf4 was negative.
Moreover, immunohistochemistry showed reactivity for CD99 while the blasts were negative for plasma cell marker, CD138, Langerhans cell marker, CD1a, cytotoxic T cell marker, perforin, pan-B marker, and pax5.
Immunohistochemically, the tumors were positive for a-inhibin (5/6) [Figure 1]d, calretinin (5/6), CD99 (6/6), and forkhead box L2 (FOXL2, 6/6) [Figure 1]e and negative for epithelial membrane antigen (0/6).
Immunohistochemical stains performed on biopsy specimens denoted positive reactivity for Bcl-2, EMA, Cytokeratin 7, Cytokeratin 19 and CD99 (Figure-2).
CD99, chromogranin A, CD45, inhibin, calretinin, CA-125, ER, PR, CK7, CK20, Moc31, Tag72, myogenin, S100, and destine were negative.
In the immunohistochemical analysis, the tumor cells were positive for LCA, CD3, CD7, CD8, and CD56, and negative for CD20, CD5, CD4, CD79a, CD10, CD99, and CK.
Positive immunohistochemistry for epithelial membrane antigen/cytokeratin and CD99. Both genders were included.
Immunohistochemistry was positive for vimentin and synaptophysin [Figure 2] while negative for pan-Cytokeratin (panCK), P-40, S-100, epithelial membrane antigen (EMA), chromogranin, melan-A, desmin, smooth muscle actin (SMA), neuron-specific enolase, CD99, CD56, CD20, CD45, and glial fibrillary acid protein (GFAP), thus confirming ESMC.